Is the agency suggesting that there are benefits of testing Ashkenazi Jewish BRCA mutations in non-Jewish women? How does the FDA justify that the benefits of testing outweigh the known risks? Well, ...

The FDA made a point to note that there are more than 1,000 cancer-related mutations in BRCA genes, and just about 2 percent of Ashkenazi Jewish women carry the three mutations in the test. They are ...

women are at low risk for developing BRCA-mutation-associated breast or ovarian cancer. Furthermore, they found fair evidence of ethical, legal, and social harms associated with testing and cited ...

Testing for BRCA mutations linked to breast and ovarian cancers could become easier and more accessible with the help of artificial intelligence, potentially allowing earlier treatment.